- Home
- JKHY vs HALO Comparison
JKHY vs HALO Comparison
Compare JKHY & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JKHY | HALO |
|---|---|---|
| Founded | 1976 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 8.1B |
| IPO Year | 2000 | 2001 |
Fundamental Metrics
Financial Performance| Metric | JKHY | HALO |
|---|---|---|
| Price | $153.78 | $81.88 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 11 |
| Target Price | ★ $197.25 | $78.64 |
| AVG Volume (30 Days) | 1.2M | ★ 1.7M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.59% | N/A |
| EPS Growth | ★ 19.31 | N/A |
| EPS | ★ 5.41 | 1.22 |
| Revenue | ★ $1,536,603,000.00 | $151,862,000.00 |
| Revenue This Year | $8.03 | $28.24 |
| Revenue Next Year | $6.39 | $12.56 |
| P/E Ratio | ★ $27.83 | $67.16 |
| Revenue Growth | ★ 7.37 | N/A |
| 52 Week Low | $121.04 | $57.68 |
| 52 Week High | $193.39 | $82.99 |
Technical Indicators
Market Signals| Indicator | JKHY | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 63.95 | 65.86 |
| Support Level | $153.74 | $67.12 |
| Resistance Level | $157.87 | $82.24 |
| Average True Range (ATR) | 4.49 | 2.49 |
| MACD | 0.09 | 0.16 |
| Stochastic Oscillator | 91.39 | 80.91 |
Price Performance
Historical ComparisonAbout JKHY Jack Henry & Associates Inc.
Jack Henry is a leading provider of core processing and complementary services, including electronic funds transfer, payment processing, and loan processing, for US banks and credit unions, with a focus on small and midsize banks. Jack Henry serves almost 1,000 banks and over 700 credit unions.
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.